Medicus Pharma regains Nasdaq bid price compliance after brief delisting notice

Medicus Pharma Ltd. disclosed in an 8-K filing that on October 23, 2026 it received a compliance notice from Nasdaq's Listing Qualifications Department stating the company had regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and that the matter was now closed.¹

The notice came just days after a more serious warning. On October 20, 2026, Medicus Pharma had received a delisting determination letter from Nasdaq staff stating that the company had not regained compliance with the minimum bid price rule and that Nasdaq planned to remove the company's common shares and warrants from the Nasdaq Capital Market. That letter traced back to an earlier notice: the company had received written notice from Nasdaq on April 21, 2026, indicating that the closing bid price of the shares had been below $1.00 per share for the previous 30 consecutive business days, triggering noncompliance, with a deadline of October 19, 2026 to regain compliance.¹ Because the company did not regain compliance by that deadline, and Nasdaq found it ineligible for a second 180-day compliance period due to not meeting the $5 million stockholders' equity requirement under Initial Listing Criteria, the company received the delisting determination letter.¹

That letter was superseded once Nasdaq confirmed compliance. Nasdaq determined that over the ten consecutive business days from October 12, 2026 through October 23, 2026, the closing bid price of the shares had met or exceeded $1.00 per share, resolving the matter.¹

The company cautioned that there is no guarantee it will keep meeting the minimum bid price rule or Nasdaq's other listing standards going forward.¹ The filing was signed by Dr. Raza Bokhari, Executive Chairman and Chief Executive Officer, dated October 23, 2026.